其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Oseltamivir CAS Registry Number: 196618-13-0 奥司他韦

CAS Name: (3R,4R,5S)-4-(Acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester
Percent Composition: C 61.51%, H 9.03%, N 8.97%, O 20.49%
Literature References: Orally active inhibitor of influenza virus neuraminidase; converted in vivo to the active acid metabolite, GS-4071. Prepn: N. W. Bischofberger et al., US 5763483 (1998 to Gilead Sci.). Degradation kinetics: R. Oliyai et al., Pharm. Res. 15, 1300 (1998). Bioavailability and pharmacokinetics: W. Li et al., Antimicrob. Agents Chemother. 42, 647 (1998). Review of structure-activity studies and clinical development: C. U. Kim, Med. Chem. Res. 8, 392-399 (1998). Clinical trial in prevention of influenza: F. G. Hayden et al., N. Engl. J. Med. 341, 1336 (1999); in treatment of acute influenza: J. J. Treanor et al., J. Am. Med. Assoc. 283, 1016 (2000). Review of potential use in influenza pandemic: P. Ward et al., J. Antimicrob. Chemother. 55, Suppl. S1, i5-i21 (2005).

Amocarzine CAS Registry Number: 36590-19-9 4-甲基-N-[4-[(4-硝基苯基)氨基]苯基]-1-哌嗪硫代甲酰胺

CAS Name: 4-Methyl-N-[4-[(4-nitrophenyl)amino]phenyl]-1-piperazinecarbothioamide
Additional Names: 4-nitro-4'-[(N-methylpiperazinyl)thiocarbonylamino]diphenylaminePercent Composition: C 58.20%,...
Literature References: Orally active macrofilaricide; derivative of amoscanate, q.v. Prepn: BE 772053 (1971 to Agripat); R. Spaun et al., US 3781290 (1973 to Ciba-Geigy). Mechanism of action study: K. P. Davies et al., Exp. Parasitol. 68, 382 (1989). HPLC determn in biological fluids: S. C. Bhatia et al., J. Chromatogr. 434, 288 (1988). Pharmacokinetics: J. B. Lecaillon et al., Br. J. Clin. Pharmacol. 30, 625, 629 (1990). Clinical trial in onchocerciasis: A. A. Poltera et al., Lancet 337, 583 (1991).

Guanadrel CAS Registry Number: 40580-59-4 胍那决尔

CAS Name: (1,4-Dioxaspiro[4.5]dec-2-ylmethyl)guanidine
Percent Composition: C 56.31%, H 8.98%, N 19.70%, O 15.00%
Literature References: Orally active postganglionic sympathetic inhibitor. Prepn: W. R. Hardie, J. E. Aaron, ZA 6706328; eidem, US 3547951 (1968, 1970 both to Cutter). Antihypertensive activity: L. Hansson et al., Clin. Pharmacol. Ther. 14, 204 (1973). In vitro adrenergic neuron blocking activity: L. Roller, Aust. J. Pharm. Sci. 5, 35 (1976). Pharmacologic study: E. M. Johnson, F. E. Hunter, Biochem. Pharmacol. 28, 1525 (1979). Effect on patients with thyrotoxicosis: S. Rubenfeld et al., Arch. Intern. Med. 138, 1106 (1978). Review of pharmacology and efficacy in hypertension: F. A. Finnerty Jr., R. N. Brogden, Drugs 30, 22-31 (1985).

Chlormadinone Acetate CAS Registry Number: 302-22-7 氯地孕酮醋酸盐

CAS Name: 17-(Acetyloxy)-6-chloropregna-4,6-diene-3,20-dione
Additional Names: 6-chloro-17-hydroxypregna-4,6-diene-3,20-dione acetate; 6-chloro-6-dehydro-17a-hydroxyprogesterone acetate; 6-chlo...
Literature References: Orally active progestogen with antiandrogenic activity; has been used in combinations as an oral contraceptive. Prepn: Brückner, DE 1075114 (1960 to E. Merck, AG); Brückner et al., Ber. 94, 1225 (1961); Sciaky, Gazz. Chim. Ital. 91, 545 (1961); GB 932153; H. J. Ringold, A. Bowers, US 3485852 (1963, 1969 both to Syntex). Endocrinological activities: D. M. Brennan, R. J. Kraay, Acta Endocrinol. 44, 367 (1963). Metabolism: S. Honma et al., Chem. Pharm. Bull. 25, 2019 (1977). Clinical evaluation in prostatic carcinoma: R. Nishimura, K. Shida, Prostate, Suppl. 1, 27 (1981); in benign prostatic hypertrophy: T. Usui et al., Acta Urol. Jpn. 27, 327 (1981), B.A. 73, 27225 (1982). Review of carcinogenicity studies: IARC Monographs 21, 365-375 (1979).

Dimethisterone CAS Registry Number: 79-64-1 双甲乙炔睾酮

CAS Name: (6a,17b)-17-Hydroxy-6-methyl-17-(1-propynyl)androst-4-en-3-one
Additional Names: 6a-methyl-17-(1-propynyl)testosterone; 6a,21-dimethyl-17b-hydroxy-17a-pregn-4-en-20-yn-3-one; 6a,21-di...
Literature References: Orally active progestogen; formerly used in combinations as oral contraceptive. Prepn: S. P. Barton et al., J. Chem. Soc. 1959, 1957; eidem, US 2939819 (1960 to Brit. Drug Houses). Structure-activity study: G. K. Suchowsky, G. Baldratti, J. Endocrinol. 30, 159 (1964). Evaluation of risk for endometrial cancer: N. S. Weiss et al., N. Engl. J. Med. 302, 551 (1980). Review of carcinogenicity studies: IARC Monographs 21, 377-385 (1979).

Cefatrizine CAS Registry Number: 51627-14-6 头孢硫脒

CAS Name: (6R,7R)-7-[[(2R)-Amino-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(1H-1,2,3-triazol-4-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Additional Names: 7-[D-a-amino-...
Literature References: Orally active semi-synthetic cephalosporin antibiotic. Prepn: G. L. Dunn, J. R. E. Hoover, DE 2316866; eidem, US 3867380 (1974, 1975 both to SKF); D. Willner, L. B. Crast, DE 2364192 (1974 to Bristol-Myers), C.A. 81, 105538 (1974); G. L. Dunn et al., J. Antibiot. 29, 65 (1976). Prepn of the propylene glycolate: M. A. Kaplan, A. P. Granatek, DE 2500385; eidem, US 3970651 (1975, 1976 both to Bristol-Myers). In vitro and in vivo antibacterial activity and pharmacokinetic behavior: P. Actor et al., ibid. 28, 594 (1975); F. Leitner et al., Antimicrob. Agents Chemother. 7, 298 (1975). General pharmacological properties: M. Matsuzaki et al., Jpn. J. Antibiot. 29, 107 (1976), C.A. 85, 311g (1976). Determn in serum and urine by HPLC: E. Crombez et al., J. Chromatogr. 173, 165 (1979). Disposition of 14C-cefatrizine in man: R. C. Gaver, G. Deeb, Drug Metab. Dispos. 8, 157 (1980). Activity and clinical use: A. J. Weinstein, Drugs 20, 137 (1980). Acute toxicity: M. Matsuzaki et al., Jpn. J. Antibiot. 29, 612 (1976), C.A. 85, 171724y (1976). Toxicological studies: ibid. 639-686, C.A. 85, 171722w-171723x (1976). Series of articles on pharmacokinetics and clinical efficacy: Drugs Exp. Clin. Res. 11, 441-462 (1985).

Brivaracetam CAS Registry Number: 357336-20-0 布瓦西坦

CAS Name: (aS,4R)-a-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide
Additional Names: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidinyl]butanamidePercent Composition: C 62.23%, H 9.50%, N 13.20%, O 15.07%
Literature References: Orally active synaptic vesicle protein 2 (SV2A) ligand; analog of levetiracetam, q.v. Prepn: E. Differding et al., WO 0162726; eidem, US 6911461 (2001, 2005 both to UCB); B. M. Kenda et al., J. Med. Chem. 47, 530 (2004). Review of pharmacology and clinical experience: B. Malawska, K. Kulig, Curr. Opin. Invest. Drugs 6, 740-746 (2005).

Tigemonam CAS Registry Number: 102507-71-1 替吉莫南

CAS Name: [[(Z)-[1-(2-Amino-4-thiazolyl)-2-[[(3S)-2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]acetic acid
Additional Names: [[[(Z)-(2-amino-4-thiazolyl)[[(3S)-...
Literature References: Orally active synthetic monosulfactam, structurally similar to the monobactam aztreonam. Prepn: C. Yoshida et al., J. Antibiot. 38, 1536 (1985); W. A. Slusarchyk et al., BE 904121; W. A. Slusarchyk, W. H. Koster, US 4638061 (1986, 1987 both to Squibb). Antibacterial spectrum and b-lactamase stability in vitro: S. K. Tanaka et al., Antimicrob. Agents Chemother. 31, 219 (1987); N.-X. Chin, H. C. Neu, ibid. 32, 84 (1988). Antibacterial activity and pharmacokinetics in animals: J. M. Clark et al., ibid. 31, 226 (1987).

Posaconazole CAS Registry Number: 171228-49-2 泊沙康唑

CAS Name: 2,5-Anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1H-1...
Literature References: Orally active triazole antifungal. Prepn: A. K. Saksena et al., WO 9517407; eidem, US 5661151 (1995, 1997 both to Schering); eidem, Tetrahedron Lett. 37, 5657 (1996). Comparative antifungal spectrum: A. Cacciapuoti et al., Antimicrob. Agents Chemother. 44, 2017 (2000). Pharmacokinetics, safety and tolerability: R. Courtney et al., ibid. 47, 2788 (2003). HPLC determn in serum: H. Kim et al., J. Chromatogr. B 738, 93 (2000). Review of development: A. K. Saksena et al. in Anti-Infectives: Recent Advances in Chemistry and Structure Activity Relationships (Royal Soc. Chem., Cambridge, 1997) pp 180-199; and clinical efficacy in fungal infections: R. Herbrecht, Int. J. Clin. Pract. 58, 612-624 (2004).

Deferasirox CAS Registry Number: 201530-41-8 地拉罗司

CAS Name: 4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acidTrademarks: Exjade (Novartis)
Percent Composition: C 67.56%, H 4.05%, N 11.25%, O 17.14%
Literature References: Orally active tridentate iron chelator. Prepn: R. Lattmann, P. Acklin, WO 9749395; eidem, US 6465504 (1997, 2002 both to Novartis); U. Heinz et al., Angew. Chem. Int. Ed. 38, 2568 (1999). HPLC determn in plasma: M. C. Rouan et al., J. Chromatogr. B 755, 203 (2001). Iron complex formation study: S. Steinhauser et al., Eur. J. Inorg. Chem. 2004, 4177. Pharmacology: C. Hershko et al., Blood 97, 1115 (2001). Clinical pharmacokinetics: R. Galanello et al., J. Clin. Pharmacol. 43, 565 (2003). Clinical trial in thalassemia: E. Nisbet-Brown et al., Lancet 361, 1597 (2003). Review of structure activity: H. Nick et al., Curr. Med. Chem. 10, 1065-1076 (2003); of preclinical and clinical experience: M. D. Cappellini, Best Prac. Res. Clin. Haematol. 18, 289-298 (2005).